Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.
Jesse MartinAlexis K WilliamsMelissa D KleinVindhya B SriramojuShivanshu MadanJoseph S RossiMegan ClarkeJonathan D CicciLarisa H CavallariKaren E WeckGeorge A StoufferAnd Craig R LeePublished in: Genetics in medicine : official journal of the American College of Medical Genetics (2019)
CYP2C19-guided escalation and de-escalation is common in a real-world setting. Continuation of clopidogrel in nonfunctional allele carriers is associated with adverse outcomes. De-escalation to clopidogrel in patients without a nonfunctional allele appears safe and warrants prospective study.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- open label
- percutaneous coronary intervention
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- coronary artery disease
- neuroendocrine tumors
- randomized controlled trial
- atrial fibrillation
- patient reported